<DOC>
	<DOCNO>NCT01009814</DOCNO>
	<brief_summary>Research Hypothesis : Administration BMS-663068 , prodrug HIV attachment inhibitor BMS-626529 , result mean decrease least 1 log10 HIV RNA Day 9 follow 8 day therapy least one dose regimen safe well tolerate Clade B HIV-1 infected subject .</brief_summary>
	<brief_title>Pharmacodynamics , Safety Pharmacokinetics BMS-663068 , HIV Attachment Inhibitor , HIV-1</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Clade B HIV1 infect subject meet follow criterion screen : Plasma HIV RNA ≥ 5,000 copies/mL CD4+ lymphocyte ≥ 200 cells/µL Antiretroviral naive experience Off ARV therapy HIV activity &gt; 8 week BMI 18 35 kg/m2 , inclusive . Not currently coinfected HCV HBV Men woman , ≥ 18 year age Woman childbearing potential ( WOCBP ) unwilling unable use acceptable method avoid pregnancy entire study period 12 week last dose study drug . WOCBP use prohibit contraceptive method include oral , injectable , implantable hormonal contraceptive agent within 12 week enrollment . Women pregnant breastfeeding . Women positive pregnancy test enrollment prior study drug intake . Sexually active fertile men use effective birth control study least 12 week last dose study drug partner WOCBP . Significant acute chronic medical illness stable control medication consistent HIV infection . Current recent ( within 3 month ) gastrointestinal disease , opinion Investigator Medical Monitor , may impact drug absorption and/or put subject risk GI tract irritation and/or bleed . Acute diarrhea last ≥ 1 day , within 3 week prior randomization . Major surgery within 4 week study drug intake . Gastrointestinal surgery could impact upon absorption study drug . Donation blood plasma blood bank clinical study ( except Screening visit follow visit le 50 mL ) within 4 week study drug intake . Blood transfusion within 4 week study drug intake . Inability tolerate oral medication . Inability venipunctured and/or tolerate venous access . Personal history clinically relevant cardiac disease , symptomatic asymptomatic arrhythmia , syncopal episode , additional risk factor torsades de pointes . Personal family history long QT syndrome . Recent ( within 6 month ) drug/alcohol abuse Any medical , psychiatric and/or social reason , opinion Investigator , would make candidate inappropriate participation . Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical lab determination consistent subject 's degree HIV infection . Evidence 2nd 3rd degree heart block screen Day 1 Positive urine drug screen Screening Day 1 without valid prescription ( subject positive cannabinoids and/or amphetamine include ) . Positive blood screen hepatitis B surface antigen . Positive blood screen hepatitis C antibody hepatitis C RNA . History significant drug allergy Exposure investigational drug placebo within 4 week study drug intake . Prescription drug within 4 week prior study drug intake , unless approve BMS medical monitor . Other drug , include overthecounter medication , vitamin and/or herbal preparation , within 1 week prior study drug intake , unless approve BMS medical monitor . Use oral , injectable implantable hormonal contraceptive agent within 12 week study drug intake . Use prescription drug OTC drug may cause GI tract irritation bleed within 2 week study drug intake , unless approve BMS medical monitor . Use alcoholcontaining beverage within 3 day prior study drug intake . Use grapefruit , grapefruitcontaining Seville orangecontaining product within 7 day prior study drug intake . Prisoners subject involuntarily incarcerate . Subjects compulsorily detain treatment either psychiatric physical illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HIV , HIV attachment inhibitor , attachment inhibitor</keyword>
</DOC>